GRK3 deficiency elicits brain immune activation and psychosis

[1]  N. Sibson,et al.  Imaging of translocator protein upregulation is selective for pro‐inflammatory polarized astrocytes and microglia , 2019, Glia.

[2]  J. Kennedy,et al.  The complement system in schizophrenia: where are we now and what’s next? , 2019, Molecular Psychiatry.

[3]  Manoj Kumar,et al.  INGE GRUNDKE-IQBAL AWARD FOR ALZHEIMER’S RESEARCH: NEUROTOXIC REACTIVE ASTROCYTES ARE INDUCED BY ACTIVATED MICROGLIA , 2019, Alzheimer's & Dementia.

[4]  M. Leboyer,et al.  Immunoneuropsychiatry — novel perspectives on brain disorders , 2019, Nature Reviews Neurology.

[5]  R. Perlis,et al.  Increased synapse elimination by microglia in schizophrenia patient-derived models of synaptic pruning , 2019, Nature Neuroscience.

[6]  Evan Z. Macosko,et al.  Single‐Cell RNA Sequencing of Microglia throughout the Mouse Lifespan and in the Injured Brain Reveals Complex Cell‐State Changes , 2019, Immunity.

[7]  G. Ecker,et al.  Discovery of Potent Inhibitors for the Large Neutral Amino Acid Transporter 1 (LAT1) by Structure-Based Methods , 2018, International journal of molecular sciences.

[8]  Alan S. Brown,et al.  Maternal Immune Activation and Neuropsychiatric Illness: A Translational Research Perspective. , 2018, The American journal of psychiatry.

[9]  R. Schwarcz,et al.  Importance of kynurenine 3-monooxygenase for spontaneous firing and pharmacological responses of midbrain dopamine neurons: Relevance for schizophrenia , 2018, Neuropharmacology.

[10]  R. Coutinho-Silva,et al.  The P2X7 Receptor in Inflammatory Diseases: Angel or Demon? , 2018, Front. Pharmacol..

[11]  JP Kesby,et al.  Dopamine, psychosis and schizophrenia: the widening gap between basic and clinical neuroscience , 2018, Translational Psychiatry.

[12]  J. L. Smalley,et al.  Adaptive and Behavioral Changes in Kynurenine 3-Monooxygenase Knockout Mice: Relevance to Psychotic Disorders , 2017, Biological Psychiatry.

[13]  K. Wu,et al.  Antagonizing the different stages of kappa opioid receptor activation selectively and independently attenuates acquisition and consolidation of associative memories , 2017, Behavioural Brain Research.

[14]  F. Di Virgilio,et al.  The P2X7 Receptor-Interleukin-1 Liaison , 2017, Front. Pharmacol..

[15]  S. Dasari,et al.  Label-Free Neuroproteomics of the Hippocampal-Accumbal Circuit Reveals Deficits in Neurotransmitter and Neuropeptide Signaling in Mice Lacking Ethanol-Sensitive Adenosine Transporter. , 2017, Journal of proteome research.

[16]  S. Erhardt,et al.  The kynurenine pathway in schizophrenia and bipolar disorder , 2017, Neuropharmacology.

[17]  Peyman Golshani,et al.  New Transgenic Mouse Lines for Selectively Targeting Astrocytes and Studying Calcium Signals in Astrocyte Processes In Situ and In Vivo , 2016, Neuron.

[18]  V. Gurevich,et al.  G protein-coupled receptor kinases as regulators of dopamine receptor functions. , 2016, Pharmacological research.

[19]  R. Mizrahi,et al.  Postmortem evidence of cerebral inflammation in schizophrenia: a systematic review , 2016, Molecular Psychiatry.

[20]  M. Goiny,et al.  Repeated LPS Injection Induces Distinct Changes in the Kynurenine Pathway in Mice , 2016, Neurochemical Research.

[21]  Raymond M. Moore,et al.  Label-Free Proteomic Analysis of Protein Changes in the Striatum during Chronic Ethanol Use and Early Withdrawal , 2016, Front. Behav. Neurosci..

[22]  J. Smoller,et al.  A genome-wide association study of kynurenic acid in cerebrospinal fluid: implications for psychosis and cognitive impairment in bipolar disorder , 2015, Molecular Psychiatry.

[23]  E. Jimenez-Mateos,et al.  microRNA targeting of the P2X7 purinoceptor opposes a contralateral epileptogenic focus in the hippocampus , 2015, Scientific Reports.

[24]  Â. R. Tomé,et al.  ATP as a multi-target danger signal in the brain , 2015, Front. Neurosci..

[25]  C. Svensson,et al.  Increased levels of IL-6 in the cerebrospinal fluid of patients with chronic schizophrenia--significance for activation of the kynurenine pathway. , 2015, Journal of psychiatry & neuroscience : JPN.

[26]  S. Schulz,et al.  Loss of Morphine Reward and Dependence in Mice Lacking G Protein–Coupled Receptor Kinase 5 , 2014, Biological Psychiatry.

[27]  Emmanuelle Gouillart,et al.  scikit-image: image processing in Python , 2014, PeerJ.

[28]  M. Goiny,et al.  Behavioral disturbances in adult mice following neonatal virus infection or kynurenine treatment – Role of brain kynurenic acid , 2014, Brain, Behavior, and Immunity.

[29]  D. Siderovski,et al.  G protein‐coupled receptor kinase‐3‐deficient mice exhibit WHIM syndrome features and attenuated inflammatory responses , 2013, Journal of leukocyte biology.

[30]  Godfrey D Pearlson,et al.  Neuropsychological impairments in schizophrenia and psychotic bipolar disorder: findings from the Bipolar-Schizophrenia Network on Intermediate Phenotypes (B-SNIP) study. , 2013, The American journal of psychiatry.

[31]  Teruhiko Higuchi,et al.  Increased cerebrospinal fluid interleukin-6 levels in patients with schizophrenia and those with major depressive disorder. , 2013, Journal of psychiatric research.

[32]  M. Cairns,et al.  Increased inflammatory markers identified in the dorsolateral prefrontal cortex of individuals with schizophrenia , 2013, Molecular Psychiatry.

[33]  M. Landén,et al.  Cerebrospinal fluid kynurenic acid is associated with manic and psychotic features in patients with bipolar I disorder , 2012, Bipolar disorders.

[34]  R. Handsaker,et al.  Genome-wide association study in a Swedish population yields support for greater CNV and MHC involvement in schizophrenia compared with bipolar disorder , 2012, Molecular Psychiatry.

[35]  R. Schwarcz,et al.  Kynurenines in the mammalian brain: when physiology meets pathology , 2012, Nature Reviews Neuroscience.

[36]  Deanna M. Barch,et al.  Cognition in schizophrenia: core psychological and neural mechanisms , 2012, Trends in Cognitive Sciences.

[37]  J. Benovic,et al.  Reduced expression of G protein-coupled receptor kinases in schizophrenia but not in schizoaffective disorder , 2011, Neurobiology of Disease.

[38]  M. Landén,et al.  Elevation of cerebrospinal fluid interleukin-1ß in bipolar disorder. , 2011, Journal of psychiatry & neuroscience : JPN.

[39]  E. Pozas,et al.  Secretogranin III is an astrocyte granin that is overexpressed in reactive glia. , 2010, Cerebral cortex.

[40]  E. Turner,et al.  Allele specific analysis of the ADRBK2 gene in lymphoblastoid cells from bipolar disorder patients. , 2010, Journal of psychiatric research.

[41]  S. Powell,et al.  Role of the NMDA-receptor in Prepulse Inhibition in the Rat , 2010, International journal of tryptophan research : IJTR.

[42]  J. Schröder,et al.  Activation of brain interleukin-1β in schizophrenia , 2009, Molecular Psychiatry.

[43]  K. Larsson,et al.  Elevated levels of kynurenic acid change the dopaminergic response to amphetamine: implications for schizophrenia. , 2009, The international journal of neuropsychopharmacology.

[44]  E. Nestler,et al.  Altered Sensitivity to Rewarding and Aversive Drugs in Mice with Inducible Disruption of cAMP Response Element-Binding Protein Function within the Nucleus Accumbens , 2009, The Journal of Neuroscience.

[45]  J. Kelsoe,et al.  Promoter Variant in the GRK3 Gene Associated with Bipolar Disorder Alters Gene Expression , 2008, Biological Psychiatry.

[46]  F. Baleux,et al.  Leukocyte analysis from WHIM syndrome patients reveals a pivotal role for GRK3 in CXCR4 signaling. , 2008, The Journal of clinical investigation.

[47]  M. Geyer,et al.  Developing translational animal models for symptoms of schizophrenia or bipolar mania , 2008, Neurotoxicity Research.

[48]  S. Erhardt,et al.  The kynurenic acid hypothesis of schizophrenia , 2007, Physiology & Behavior.

[49]  D. Collier,et al.  Association analysis of GRK3 gene promoter variants in cocaine abuse , 2007, Psychiatric genetics.

[50]  M. Low,et al.  Role of dopamine D1 and D2 receptors in CRF-induced disruption of sensorimotor gating , 2007, Pharmacology Biochemistry and Behavior.

[51]  J. Gogos,et al.  Modeling Madness in Mice: One Piece at a Time , 2006, Neuron.

[52]  D. Bucci,et al.  Increased concentration of cerebral kynurenic acid alters stimulus processing and conditioned responding , 2006, Behavioural Brain Research.

[53]  Liqin Wang,et al.  ATP stimulates GRK-3 phosphorylation and beta-arrestin-2-dependent internalization of P2X7 receptor. , 2005, American journal of physiology. Cell physiology.

[54]  M. Geyer,et al.  Endogenous kynurenic acid disrupts prepulse inhibition , 2004, Biological Psychiatry.

[55]  R. Yolken,et al.  Expression of the kynurenine pathway enzyme tryptophan 2,3-dioxygenase is increased in the frontal cortex of individuals with schizophrenia , 2004, Neurobiology of Disease.

[56]  Marc G Caron,et al.  Dopaminergic Supersensitivity in G Protein-Coupled Receptor Kinase 6-Deficient Mice , 2003, Neuron.

[57]  L. Clerkin,et al.  Micromolar Brain Levels of Kynurenic Acid are Associated with a Disruption of Auditory Sensory Gating in the Rat , 2003, Neuropsychopharmacology.

[58]  P. M. Wall,et al.  Infralimbic kappa opioid and muscarinic M1 receptor interactions in the concurrent modulation of anxiety and memory , 2002, Psychopharmacology.

[59]  K. Blennow,et al.  Kynurenic acid levels are elevated in the cerebrospinal fluid of patients with schizophrenia , 2001, Neuroscience Letters.

[60]  S. Ammon,et al.  Distribution of G-protein-coupled receptor kinase (GRK) isoforms 2, 3, 5 and 6 mRNA in the rat brain. , 2001, Brain research. Molecular brain research.

[61]  R. Schwarcz,et al.  Increased cortical kynurenate content in schizophrenia , 2001, Biological Psychiatry.

[62]  M. Laruelle,et al.  Increased dopamine transmission in schizophrenia: relationship to illness phases , 1999, Biological Psychiatry.

[63]  S. K. Malhotra,et al.  Reactive astrocytes: cellular and molecular cues to biological function , 1997, Trends in Neurosciences.

[64]  A. Malhotra,et al.  Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: evidence from a novel positron emission tomography method. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[65]  J. Krystal,et al.  Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[66]  T. Dawson,et al.  The G-protein-coupled receptor kinases beta ARK1 and beta ARK2 are widely distributed at synapses in rat brain , 1992, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[67]  A Carlsson,et al.  Effect of hypercapnia and hypocapnia on tryptophan and tyrosine hydroxylation in rat brain. , 1977, Acta physiologica Scandinavica.

[68]  N. Parameswaran,et al.  G Protein-Coupled Receptor Kinases in the Inflammatory Response and Signaling. , 2017, Advances in immunology.

[69]  Jianxin Shi,et al.  Genetic relationship between five psychiatric disorders estimated from genome-wide SNPs , 2013, Nature Genetics.

[70]  A. Mushegian,et al.  G protein-coupled receptor kinases: more than just kinases and not only for GPCRs. , 2012, Pharmacology & therapeutics.

[71]  M. Geyer,et al.  Genetic models of sensorimotor gating: relevance to neuropsychiatric disorders. , 2012, Current topics in behavioral neurosciences.

[72]  M. van den Buuse.  Modeling the positive symptoms of schizophrenia in genetically modified mice: pharmacology and methodology aspects. , 2010, Schizophrenia bulletin.

[73]  J. Kelsoe,et al.  Evidence that a single nucleotide polymorphism in the promoter of the G protein receptor kinase 3 gene is associated with bipolar disorder , 2003, Molecular Psychiatry.